Dara Azar
Stock Analyst at Stifel Nicolaus
(2.27)
# 3,175
Out of 4,630 analysts
15
Total ratings
50%
Success rate
5.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dara Azar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Rated: Buy | $80 → $82 | $60.46 | +35.63% | 3 | Aug 6, 2026 | |
| SMMT Summit Therapeutics | Maintained: Buy | $38 | $13.96 | +172.21% | 7 | Jul 28, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $325 | $88.66 | +266.57% | 5 | Jun 2, 2026 |
Enliven Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $80 → $82
Current: $60.46
Upside: +35.63%
Summit Therapeutics
Jul 28, 2026
Maintained: Buy
Price Target: $38
Current: $13.96
Upside: +172.21%
Inhibrx Biosciences
Jun 2, 2026
Maintained: Buy
Price Target: $325
Current: $88.66
Upside: +266.57%